"Nobody ever got fired for hiring the big agency." Pharma clients say it with a half-smile, sometimes with a sigh. It is the unspoken rule that keeps specialist agencies out of serious consideration, even when the last network engagement ran three months late, the account team changed twice, and the final deliverable was fine rather than good.
Fine is safe. Safe is what procurement rewards. And the person signing a seven-figure contract is personally accountable for the outcome, so picking the known name is the lowest-risk career move regardless of whether it is the best commercial move.
The pattern is well documented. Writing in The Drum, agency commentators note that procurement departments regularly assess independent agencies as high risk compared to network competitors, with supplier financial size being one of the most common risk proxies. Size stands in for safety, even when it should not.
Three forces keep the default in place. The first is accountability asymmetry. A brand director who picks a network agency and gets mediocre work can point to the logo and shrug. The same director who picks a specialist and gets the same mediocre work owns the decision personally.
The second is procurement scoring. Risk frameworks weight financial size, global footprint, and roster breadth. A specialist with 60 pharma consultants scores worse on a spreadsheet than a network with 6,000 generalists, even if only four of those 6,000 will ever touch the account.
The third is the myth of one-stop coverage. The assumption is that a holding company can handle everything, so consolidation reduces vendor risk. In practice, Pharmaceutical Executive has reported that many brand leaders are now embracing a "prosolidation" model, deliberately adding independent agencies back into the mix because consolidation created new risks around innovation and flexibility.
Specialists win on the dimensions procurement scoring ignores. Pharma-only focus means every consultant has worked inside the regulatory constraints before. There is no onboarding curve to explain why a claim needs a reference, why localization is not translation, or why the MLR reviewer flagged a visual.
At Promedia, the model is built around this. The agency works exclusively with pharmaceutical clients, with consultants certified in Veeva CRM, ISO standards, and Scrum, and the organization itself is SBTi certified. End-to-end project teams are assembled to run initiatives autonomously or integrated with client operations, with scalable resourcing that flexes up or down against project scope. That depth is hard to replicate when a generalist account is one of forty on a planner's desk.
Industry voices echo the point. AbelsonTaylor has argued that innovation in pharma advertising is not about who has the biggest toolbox but about how quickly and confidently an agency can act within regulatory constraints, an area where independents often outperform networks. Branch Boston's research on agency selection reaches a similar conclusion: healthcare specialists consistently outperform generalists on regulatory compliance, campaign effectiveness, and client satisfaction, and team stability matters more than headcount.
Medical, Legal and Regulatory review is where agency quality becomes visible. Most MLR cycles do not fail because the content is wrong. They fail because the process around the content was wrong from the start. A specialist with pharma-native workflows designs the process to pre-empt the rework a generalist creates.
Promedia's own guidance on surviving the MLR cycle points to three habits that cut rounds:
The measurable difference, fewer rounds, shorter approval windows, cleaner first drafts, is exactly the kind of evidence a brand manager can take back to procurement.
The assumption that only networks can run multi-market work is the strongest version of the big-agency default. It is also the most testable. Promedia has launched a website for TK2d, a rare mitochondrial disease, across multiple languages, where the brief was not "build a website" but "create a place where patients, caregivers, and doctors can actually understand what they are facing." Rare disease, multi-market, multi-language, delivered by a specialist team.
The patient engagement track record points the same direction: more than ten pharma brands, 50,000-plus patients reached, and feedback from colleagues across country affiliates that has been consistently positive. Multi-market execution is a process problem, not a headcount problem. A specialist with a tight team, a shared content system, and a single point of accountability often ships cleaner work across fifteen markets than a network coordinating across fifteen offices.
By flipping the risk calculation. Not with a better pitch deck. With one project the client can defend internally when someone asks why they did not just go with the big name.
That means one account manager who answers the same day. One deliverable that did not need a rescue call. One MLR cycle that closed in two rounds instead of five. Pharmaceutical Marketing commentary notes that procurement teams are increasingly open to flexible commercial arrangements, selecting agencies project by project rather than through long-term retainers. That shift is the opening. Specialists who use a first project to prove the model, then the second to prove it was not luck, convert on the third.
No. Large agencies are safer on procurement scorecards because size proxies for financial stability. On actual delivery risk, which is where mediocre work, team turnover, and missed deadlines live, specialists often perform better because the account is strategically important to them rather than one of forty. Safety on paper is not the same as safety in execution.
Most frameworks weight financial size, global footprint, client roster, compliance certifications, and insurance coverage. These measure organizational risk, not delivery risk. Smart brand teams add their own criteria: account team tenure, pharma-only experience, MLR cycle performance on prior work, and reference calls with clients of similar scale. A specialist that holds relevant certifications and runs retainer or project engagements above the €150,000 threshold meets procurement requirements while outperforming on the criteria that actually affect outcomes.
Team stability, direct access to senior decision-makers, pharma-native regulatory fluency, and a demonstrable track record of reducing MLR rounds. Ask who will be on the account in year two, not just at pitch. Ask for examples where the agency pushed back on a brief for regulatory reasons. Ask how approved content is stored and reused across markets. The answers separate specialists from generalists quickly.
Yes, when the agency is built for it. Multi-market execution depends on a shared content system, a validate-globally-then-localize workflow, and a single accountable team rather than a coordination layer across offices. Specialists running rare disease launches across multiple languages, or patient engagement programs across ten-plus brands and 50,000-plus patients, demonstrate the model works at scale.
If your last network engagement delivered fine-not-great work, the default is doing you a disservice. The way out is not to replace the network tomorrow. It is to carve out one project, one market, or one asset type where a specialist can prove the model on a contained scope. If the work is clearly better, the internal argument for the next project writes itself.
Promedia works with pharma brand teams on exactly this kind of proving ground, from MLR-optimized content systems to multi-market patient engagement launches. If you are weighing how to introduce a specialist into a network-dominated roster, we are happy to talk through what a first project could look like.
One short email when we publish. No spam, no sales pitch. Unsubscribe whenever.
